A citation-based method for searching scientific literature

George S Sheppard, Le Wang, Steven D Fidanze, Lisa A Hasvold, Dachun Liu, John K Pratt, Chang H Park, Kenton Longenecker, Wei Qiu, Maricel Torrent, Peter J Kovar, Mai Bui, Emily Faivre, Xiaoli Huang, Xiaoyu Lin, Denise Wilcox, Lu Zhang, Yu Shen, Daniel H Albert, Terrance J Magoc, Ganesh Rajaraman, Warren M Kati, Keith F McDaniel. J Med Chem 2020
Times Cited: 55







List of co-cited articles
569 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Emily J Faivre, Keith F McDaniel, Daniel H Albert, Srinivasa R Mantena, Joshua P Plotnik, Denise Wilcox, Lu Zhang, Mai H Bui, George S Sheppard, Le Wang,[...]. Nature 2020
165
70

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
63

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Nicola R Harker, Enid Y N Lam, Chun-Wa Chung, Paul Bamborough, Massimo Petretich,[...]. Science 2020
169
61

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012
49

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
848
41

The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
Jonathan T Seal, Stephen J Atkinson, Helen Aylott, Paul Bamborough, Chun-Wa Chung, Royston C B Copley, Laurie Gordon, Paola Grandi, James R J Gray, Lee A Harrison,[...]. J Med Chem 2020
28
78

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Sarah Picaud, Christopher Wells, Ildiko Felletar, Deborah Brotherton, Sarah Martin, Pavel Savitsky, Beatriz Diez-Dacal, Martin Philpott, Chas Bountra, Hannah Lingard,[...]. Proc Natl Acad Sci U S A 2013
294
38

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Christopher R Wellaway, Paul Bamborough, Sharon G Bernard, Chun-Wa Chung, Peter D Craggs, Leanne Cutler, Emmanuel H Demont, John P Evans, Laurie Gordon, Bhumika Karamshi,[...]. J Med Chem 2020
27
74

Drug Discovery Targeting Bromodomain-Containing Protein 4.
Zhiqing Liu, Pingyuan Wang, Haiying Chen, Eric A Wold, Bing Tian, Allan R Brasier, Jia Zhou. J Med Chem 2017
166
36

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins.
Alex Preston, Stephen Atkinson, Paul Bamborough, Chun-Wa Chung, Peter D Craggs, Laurie Gordon, Paola Grandi, James R J Gray, Emma J Jones, Matthew Lindon,[...]. J Med Chem 2020
27
74

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
34

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
Robert J Watson, Paul Bamborough, Heather Barnett, Chun-Wa Chung, Rob Davis, Laurie Gordon, Paola Grandi, Massimo Petretich, Alex Phillipou, Rab K Prinjha,[...]. J Med Chem 2020
37
51

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
207
32

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Robert P Law, Stephen J Atkinson, Paul Bamborough, Chun-Wa Chung, Emmanuel H Demont, Laurie J Gordon, Matthew Lindon, Rab K Prinjha, Allan J B Watson, David J Hirst. J Med Chem 2018
53
30

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
29

BET inhibitors: a novel epigenetic approach.
D B Doroshow, J P Eder, P M LoRusso. Ann Oncol 2017
186
23

GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family.
Alex Preston, Stephen J Atkinson, Paul Bamborough, Chun-Wa Chung, Laurie J Gordon, Paola Grandi, James R J Gray, Lee A Harrison, Antonia J Lewis, David Lugo,[...]. ACS Med Chem Lett 2020
15
86

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Keith F McDaniel, Le Wang, Todd Soltwedel, Steven D Fidanze, Lisa A Hasvold, Dachun Liu, Robert A Mantei, John K Pratt, George S Sheppard, Mai H Bui,[...]. J Med Chem 2017
77
23

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
23


AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Garrett W Rhyasen, Maureen M Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L Dale, Scott Boiko, Tony Cheung, Jingwen Zhang,[...]. Mol Cancer Ther 2016
99
21

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Brian K Albrecht, Victor S Gehling, Michael C Hewitt, Rishi G Vaswani, Alexandre Côté, Yves Leblanc, Christopher G Nasveschuk, Steve Bellon, Louise Bergeron, Robert Campbell,[...]. J Med Chem 2016
132
21

Structure and ligand of a histone acetyltransferase bromodomain.
C Dhalluin, J E Carlson, L Zeng, C He, A K Aggarwal, M M Zhou. Nature 1999
21

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Sophie Postel-Vinay, Karin Herbschleb, Christophe Massard, Victoria Woodcock, Jean-Charles Soria, Annette O Walter, Flavio Ewerton, Martine Poelman, Neil Benson, Matthias Ocker,[...]. Eur J Cancer 2019
49
22

Clinical trials for BET inhibitors run ahead of the science.
Guillaume Andrieu, Anna C Belkina, Gerald V Denis. Drug Discov Today Technol 2016
158
20

Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression.
Mar Gacias, Guillermo Gerona-Navarro, Alexander N Plotnikov, Guangtao Zhang, Lei Zeng, Jasbir Kaur, Gregory Moy, Elena Rusinova, Yoel Rodriguez, Bridget Matikainen,[...]. Chem Biol 2014
91
20

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
20

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Kevin G McLure, Emily M Gesner, Laura Tsujikawa, Olesya A Kharenko, Sarah Attwell, Eric Campeau, Sylwia Wasiak, Adam Stein, Andre White, Eric Fontano,[...]. PLoS One 2013
140
18

Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Anand Divakaran, Siva K Talluri, Alex M Ayoub, Neeraj K Mishra, Huarui Cui, John C Widen, Norbert Berndt, Jin-Yi Zhu, Angela S Carlson, Joseph J Topczewski,[...]. J Med Chem 2018
40
25


Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
Olivier Mirguet, Romain Gosmini, Jérôme Toum, Catherine A Clément, Mélanie Barnathan, Jean-Marie Brusq, Jacqueline E Mordaunt, Richard M Grimes, Miriam Crowe, Olivier Pineau,[...]. J Med Chem 2013
211
18

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016
284
18

Epigenetic drug discovery: breaking through the immune barrier.
David F Tough, Paul P Tak, Alexander Tarakhovsky, Rab K Prinjha. Nat Rev Drug Discov 2016
95
16

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
Aristeidis Chaidos, Valentina Caputo, Katerina Gouvedenou, Binbin Liu, Ilaria Marigo, Mohammed Suhail Chaudhry, Antonia Rotolo, David F Tough, Nicholas N Smithers, Anna K Bassil,[...]. Blood 2014
141
16

Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Chun-Wa Chung, Herve Coste, Julia H White, Olivier Mirguet, Jonathan Wilde, Romain L Gosmini, Chris Delves, Sylvie M Magny, Robert Woodward, Stephen A Hughes,[...]. J Med Chem 2011
240
16

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni,[...]. Clin Cancer Res 2015
186
16

RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Olesya A Kharenko, Emily M Gesner, Reena G Patel, Karen Norek, Andre White, Eric Fontano, Robert K Suto, Peter R Young, Kevin G McLure, Henrik C Hansen. Biochem Biophys Res Commun 2016
38
23

RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Ravi Jahagirdar, Sarah Attwell, Suzana Marusic, Alison Bendele, Narmada Shenoy, Kevin G McLure, Dean Gilham, Karen Norek, Henrik C Hansen, Raymond Yu,[...]. Mol Pharmacol 2017
36
25

Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
Deheng Chen, Tian Lu, Ziqin Yan, Wenchao Lu, Feilong Zhou, Xilin Lyu, Biling Xu, Hualiang Jiang, Kaixian Chen, Cheng Luo,[...]. Eur J Med Chem 2019
18
50

BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.
Kalung Cheung, Geming Lu, Rajal Sharma, Adam Vincek, Ruihua Zhang, Alexander N Plotnikov, Fan Zhang, Qiang Zhang, Ying Ju, Yuan Hu,[...]. Proc Natl Acad Sci U S A 2017
65
16

Structural basis of PROTAC cooperative recognition for selective protein degradation.
Morgan S Gadd, Andrea Testa, Xavier Lucas, Kwok-Ho Chan, Wenzhang Chen, Douglas J Lamont, Michael Zengerle, Alessio Ciulli. Nat Chem Biol 2017
457
16

Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
Jonathan Seal, Yann Lamotte, Frédéric Donche, Anne Bouillot, Olivier Mirguet, Françoise Gellibert, Edwige Nicodeme, Gael Krysa, Jorge Kirilovsky, Soren Beinke,[...]. Bioorg Med Chem Lett 2012
135
16

Bromodomain biology and drug discovery.
Nilesh Zaware, Ming-Ming Zhou. Nat Struct Mol Biol 2019
91
16

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018
250
16

BET domain co-regulators in obesity, inflammation and cancer.
Anna C Belkina, Gerald V Denis. Nat Rev Cancer 2012
481
16


Targeting Brd4 for cancer therapy: inhibitors and degraders.
Yingchao Duan, Yuanyuan Guan, Wenping Qin, Xiaoyu Zhai, Bin Yu, Hongmin Liu. Medchemcomm 2018
68
16

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Georg E Winter, Dennis L Buckley, Joshiawa Paulk, Justin M Roberts, Amanda Souza, Sirano Dhe-Paganon, James E Bradner. Science 2015
849
16

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.
Zhiqing Liu, Haiying Chen, Pingyuan Wang, Yi Li, Eric A Wold, Paul G Leonard, Sarah Joseph, Allan R Brasier, Bing Tian, Jia Zhou. J Med Chem 2020
26
34

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, Patricia LoRusso, Russell Szmulewitz, Sapna Pradyuman Patel, Primo N Lara, Xiaotian Chen, Beibei Hu, Kevin J Freise,[...]. Clin Cancer Res 2019
80
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.